Several variants of EGFR-targeting affibodies [22] demonstrated higher tumor uptake (range between 2.7 and 8.6%ID/g at 3 h after injection), and tumor-to-blood ratios were also higher for these tracers (range between 7 and 12). Here, EGFR is linked to neoplasm.